Phase 3
Completed N=77
Drug Treatment for Pathologic Gambling Disorder
Gambling
Source: ClinicalTrials.gov NCT00053677 ↗
Enrolled (actual)
77
Serious AEs
0.0%
Results posted
Oct 2017
Primary outcomePrimary: Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS) — 16.9; 18.6; 9.7; 12.9 units on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will establish the best dose of the drug naltrexone to treat patients with Pathological Gambling Disorder (PGD) and severe urge symptoms.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Yale-Brown Obsessive Compulsive Scale for Pathological Gambling (PG-YBOCS) |
16.9; 18.6; 9.7; 12.9 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnostic and Statistical Manual IV criteria for Pathological Gambling Disorder
- Moderate or severe gambling urge assessed by the Gambling Symptom Assessment Scale
- No psychiatric drug use for 2 weeks or more
- Score >= 5 on The South Oaks Gambling Screen
- Hamilton Depression Rating Scale and Anxiety Rating score < 26. An increase (up to 10 points) of the scores is allowed unless the subject shows the risks of suicide.
- Completion of complete blood count, urinalysis, liver and thyroid function tests, and pregnancy tests, with no evidence of significant lab abnormalities
- Reliable birth control in women of child-bearing potential
Data sourced from ClinicalTrials.gov (NCT00053677). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.